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Résumé 
  
La bléomycine est un antibiotique cytotoxique, son potentiel génotoxique est 
plus important quand elle est utilisée en combinaison avec des agents 
antinéoplasiques sur le cancer testiculaire, que sur les autres types qui développent 
souvent une résistance envers la drogue. Notre but consiste alors de mettre en 
évidence ce mécanisme de résistance en utilisant l’organisme modèle Saccharomyces 
cerevisiae. 
Nous avons démontré au sein de notre laboratoire, que les levures délétées au 
niveau de leur coactivateur transcriptionnel Imp2, présentent une hypersensibilité à la 
bléomycine, en raison de son accumulation toxique dans la cellule. Ceci suggère que 
Imp2 pourrait réguler l’expression d’une ou de plusieurs pompes à efflux, capables 
d’expulser la bléomycine à l’extérieur de la cellule. 
Pour tester notre hypothèse, nous avons recherché des suppresseurs 
multicopies capables de restaurer la résistance à la bléomycine chez le mutant imp2, 
et c’est ainsi que nous avons identifié l'activateur transcriptionnel Yap1. Ce dernier se 
lie à une région spécifique localisée au niveau du  promoteur et permet d’activer 
l'expression d'un sous-ensemble de gènes, codant pour des pompes à efflux, 
impliquées dans la résistance aux drogues. 
Selon la littérature, au moins 27 pompes à efflux ont été identifiées chez la 
levure Saccharomyces cerevisiae, certaines d’entre elles disposent du site de liaison 
pour Yap1, tels que Qdr3, Tpo2 et Tpo1. Afin de déterminer si une de ces pompes 
expulse la bléomycine, nous avons créé des mutations simples et doubles en 
combinaison avec IMP2, aussi nous avons verifié si les mutants étaient sensibles à la 
drogue et enfin, nous avons testé si la surexpression de Yap1 pouvait restaurer le 
phénotype sauvage chez ces mutants, via l’activation de pompes à efflux.  
 
Mots clés: bléomycine, cancer testiculaire, Imp2, Yap1, Tpo1, résistance à la drogue. 
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Abstract 
 
Bleomycin is a cytotoxic antibiotic that, when used in combination with 
antineoplastic agents, has more genotoxic potential on testicular cancer than other 
types of cancer, which often develop resistance to the drugs. Our goal is to identify 
the resistance mechanism, using the organism Saccharomyces cerevisiae as a model. 
In our laboratory, we have demonstrated that deleted yeast strains on their 
transcriptional coactivator Imp2 have presented hypersensitivity to bleomycin due to 
the toxic accumulation inside the cell. This led us to believe that Imp2 might regulate 
the expression of one or more efflux pumps capable of expelling bleomycin outside 
the cell. 
To test our hypothesis, we sought multi-copy of suppressors capable of 
restoring bleomycin resistance in the mutant imp2. As a result we identified the 
transcriptional activator Yap1, which binds to a specific region within the promoter 
and activates the expression of subset of genes, encoding efflux pumps that are 
involved in drug resistance. 
Based on the literature, at least 27 efflux pumps have been identified in 
Saccharomyces cerevisiae. Some of these efflux pumps have binging sites for Yap1; 
such as Qdr3, Tpo2 and Tpo1. To determine whether or not one of these pumps 
expelled bleomycin, we proceded by single and double mutations in combination 
with IMP2. We also verified if these single and double mutants were sensitive to the 
drug, and then we have examined whether the overexpression of Yap1 could restore 
the wild phenotype in these mutants through the activation of efflux pumps. 
 
Key words: Bleomycin, testicular cancer, Imp2, Yap1, Tpo1, drug resistance. 
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 2 
1  Introduction 
 
1.1 Bleomycin        
 
Bleomycins are a family of glycopeptide antibiotics that were originally 
isolated as a fermentation product from Streptomyces verticillis cultures [1, 2] by 
Umezawa et al. in 1966 [1, 3]. Because of their cytotoxicity effect resulted from their 
DNA cleavage potency, they are considered as powerful anti-cancer drugs [1, 4, 5].  
The clinically used compound is bleomycin sulfate (bleonoxane), which is a 
combination of 3 analogues of bleomycin – A2 (roughly 60%), B2 (approximately 
30%) and minor amount of A5 [6]. Bleomycin has been used clinically since the early 
1970’s [7] to treat efficiently a number of malignancies, namely lymphomas, 
squamous cell carcinoma of the cervix, head, neck, and Hodgkin’s disease [5, 8-11]. 
In combination therapy with cisplatin and etoposide, bleomycin is also used to treat  
testicular cancer, in spite of its side effect in inducing lung fibrosis in 10% of patients 
[12]. It is curative for 80 % patients [13, 14]; however, the 20 % remaining develop 
resistance towards the drug, limiting its therapeutic efficacity [13, 15].  
 
Though the mechanism(s) describing the development of drug resistance 
towards bleomycin have not yet been found, a number of mechanisms whereby cells 
can become resistant to cytotoxic drugs include: 1) reduced permeability or uptake; 2) 
enhanced efflux; 3) inactivation of the drug by elevated levels of bleomycin 
hydrolase; 4) enhanced repair of bleomycin induced DNA lesions [16-20]. 
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Depending on the level of the resistance they provide, most of these mechanisms that 
lead to resistance play a significant role in declining the efficacy of cancer 
chemotherapy. 
 
1.1.1 Bleomycin structure  
 
All bleomycin family members have a common structure but differ only in 
their amino acid side-chain at their C-terminal [21]. An example of bleomycin 
analogue A5 is illustrated in figure 1. Bleomycin A5 comprises three functional 
domains: C-terminal domain, N-terminal domain and the carbohydrate moety. 
 The C-terminal DNA-binding domain comprises a bithiazole moiety and a 
positively charged polyamine-like region [22-27]. It has been suggested that these 
two portions interact together with the DNA and might be involved in the sequence 
selective DNA cleavage.This was supported by previous studies showing that the 
substitution of bithiazole moity by two coumpounds; thriazole [28], and 
monothiazole [29]  respectively resulted in altering the sequence from 5’-GC-3’ to 5’-
GT-3’ [28] and loosing the ability of selective DNA cleavage [29]. 
 The N-terminal metal-binding domain consists on β-hydroxyhistidine and 
pyrimidoblamic acid moieties [30]. It binds to the molecular oxygen as well as both 
iron and cobalt which are respectively redox-active and non-redox-active metal ions 
[24, 26, 31-34]. It interacts preferentially with iron, as it enhances the production of 
DNA lesions [35, 36]. 
 The role of the carbohydrate moiety remains unknown, although some recent 
studies have shown that when bleomycin was lacking this domain, its DNA cleavage 
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potency became low [25, 37-39], and the ration of DSB to SSB was then reduced 
given that the deglycobleomycin generates essencially SSB, which were 300 fold less 
cytotoxic than the DSB [38]. 
 
 
Figure 1. Bleomycin A5 structure 
Bleomycin comprises 3 major domains: N-terminal metal binding domain, C-terminal 
metal binding domain and the carbohydrate moiety [40]. 
 
 
1.1.2 Mechanism of action of bleomycin 
 
Bleomycin requires molecular oxygen and iron metal as a co-factor [41] to 
generate a narrow set of DNA lesions [42]. The reduced form of iron (Fe II) binds to 
the iron metal binding domain of bleomycin and becomes oxidized in the presence of 
oxygen. The complex (Blm–Fe(II)–O2) is then converted to an activated form [43, 44]  
that is able to intercalate with the DNA as an oxidant causing an abstraction of the 
hydrogen atom from the 4’ carbon of deoxyribose, and finally resulting in the  
 5 
production of  an intermediate radical (Fig. 2). 
Depending on the absence or presence of oxygen, this intermediate will be 
either oxidized, generating oxidized apurinic/apyrimidinic (AP) sites [42, 45, 46], or 
reacts with O2 to form a 4’peroxy radical that is reduced to a 4’hydroperoxide. The 
resulting product goes through chemical transformations, eventually inducing a single 
stranded DNA cleavage with 3’phosphoglycolate/5’-phosphate (3.-PG/5.-P) ends [42, 
45, 47, 48], (Fig. 3), at a pyrimidine base (thymine or cytosine) to a guanine (5'-G-Py-
3') [49]. Depending on the site of the residue 3’, which is derived from the primary 
cleavage [50], a secondary cleavage occurs generating either 5'-staggered ends for the 
sequence 5'-G-Py-Pu-3 ', or blunt ends for  5'-G-Py-Py-3’ (Fig. 4). 
Such DNA lesions are considered highly genotoxic, and it is still not clear 
how cells could develop drug resistance to bleomycin. 
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Figure 2. Mechanism of generation activated bleomycin 
Bleomycin binds to the iron metal by forming a bleomycin-Fe (II) complex (1), this 
complex becomes activated once Fe (II) is intracellularly oxidized (2), generating free 
radicals and causing DNA lesions (3). 
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Figure 3. Mechanism of generation DNA lesions 
Once bleomycin is activated, it intercalates with DNA, abstracts a hydrogen atom 
from the carbon 4’ of desoxyribose and generates a radical intermediate. Depending 
on the availability of oxygen; the radical intermediate will generate either oxidative 
AP sites or single and double-strand break. Nature review [6]. 
 8 
 
 
Figure 4. Bleomycin generates double strand breaks 
The activated bleomycin initiates a single-stranded DNA cleavage, followed by a 
second cleavage that depends on the residue 3’ created during the first cleavage. 
Nature review[6].  
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1.2  Mechanisms of resistance 
Up to now, there is not a well accepted theory that is able to explain with 
certainty why some types of cancer respond better to the bleomycin treatment than 
those that are resistant. Cancer cells are selectively killed by anticancer drugs, 
because most of them are defective in their checkpoint responses [51-54], and 
proliferate rapidely; they would not have sufficient time to repair the DNA damage, 
and therefore keep dividing despite of unrepaired DNA.  Furthermore, some cancer 
cells are repair-defective [55-62] in the first place, and this leads to their genomic 
instability [62-64].  
Although, normal cells are continuously subjected to DNA damage, as well as 
cancer cells, they possess several pathways that lead to their resistance [65]. The 
identification of these pathways could provide us with an insight into the mechanism 
of increasing the cytotoxicity of bleomycin in specific cancer cells. 
 
1.2.1 DNA repair pathways 
 
Bleomycin is a radiomimetic agent that generates mostly the same types of 
DNA damages (DSB and AP sites) caused by ionizing radiations (IR) [66]. Its 
cytotoxicity is particularly related to its potency to induce DSB [67]. 
 Unlike the IR, where the ratio of DSB to SSB is 1/20 [68], each molecule of 
bleomycin generates in vivo and in vitro 8 to 10 DNA breaks [50], and for 6-10 SSB, 
1 DSB is produced [69]. In recent studies on Chinese hamster lung fibroblasts, it has 
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been demonstrated that bleomycin induced 2-3 times more DSB in G1 or G2/M 
phases than in S-phase [70]. 
In yeast, depending on the type of damage generated by bleomycin, whether it 
is single or double cleavage, cells can select the appropriate pathway to repair its 
DNA damage. When the double strand breaks (DSB) occur, the DNA repair 
predominantly proceeds through the homologuous recombination pathway [71] where 
Rad52 epistasis group proteins (Rad51, Rad52, Rad54, Rad55/57 and Rad59) are 
involved [72, 73].  
In the case of a single strand break and oxidized AP site, the DNA repair 
process is carried out by base excision repair (BER) pathway [74], which required the 
major apurinic/apyrimidinic endonuclease 1(Apn1)  [75, 76] homologous to APN1 in 
human cells.This pathway consists of the following: first of all, the BER pathway is 
initiated by the glycosylase enzyme necessary for the recognition and the excision of 
a damaged base that generates an AP site [77, 78], which in turn recruits the 
endonuclease Apn1. This latter cleaves the 5’ phosphodiester bonds to the AP site 
yielding free 3′-hydroxyl and 5′-deoxyribose phosphate moieties [79, 80] that will be 
subsequently removed by DNA deoxyribophosphodiesterase (dRpase).  Depending on 
the total number of nucleotides that are excised through the repair process, the 
resulting gap is filled either by one single nucleotide (through a short-patch sub-
pathway), or by two or more new synthesized nucleotides. These are incorporated by 
DNA polymerase through long-patch sub-pathway and sealed with DNA ligase [81], 
(Fig. 5). 
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Recent studies demonstrated that the expression level of APN1 determined by 
immunohistochemical analysis is increased in a number of human cancer cells, such 
as the prostate and the lung cancers [82-85]. It has also been supported that the 
increased level of APN1 observed in testicular cancer correlates with bleomycin 
resistance by providing a 3-fold increase in protection against bleomycin [86]. 
 
 
 
 
 
 
Figure 5. Base excision repair pathway 
During the BER pathway, the glycolase recognizes and excises the DNA damage 
generating an AP site that is cleaved by Apn1 endonuclease, then a DNA polymerase 
is recruited to fill the gap by synthesizing one or more nucleotides through the short 
pach or the long patch. J Biol Chem. [81]. 
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1.2.2 Major mechanisms leading to resistance 
 
Current findings from Ramotar’s lab raised the possibility that the resistance 
to bleomycin can be related to drug efflux as well as drug uptake. As it has been 
demonstrated, when the AGP2 gene – a transporter of bleomycin – was mutated, it 
reduced the drug uptake, and hence induced an (~3000-fold) increase in resistance 
with high efficiency [87]. 
A similar effect is induced by the overexpression of an efflux pump that 
extrudes the drug from the cytoplasm, and thus, reduces the effective intracellular 
concentration [88, 89]. In agreement, it has been shown recently that the principal 
mechanism leading to the resistance of stem cells to chemotherapy is related to the 
expression of multi-functional efflux transporters in human stem cells [90]. 
 
1.3 Transcriptional co-activator Imp2 provides resistance 
 
IMP2 is a well known gene that provides resistance against bleomycin among 
the S.cerevisiae genes. It was characterized as a gene encoding a transcriptional co-
activator that turns on the gene expression of maltase permease (MALS), maltose 
permease (MALT) and galactose permease (GAL2) [91, 92]. 
 
It has been demonstrated that the IMP2 gene is required to mediate cellular 
resistance to oxidative DNA damaging agents that generate free radicals such as H2O2 
and bleomycin. When IMP2 is deleted, mutants become 15-fold hypersensitive to 
bleomycin [93]. Recent findings suggest that the hypersensitivity exhibited by imp2 
mutants towards bleomycin, is not due to the expression deficiency of drug efflux 
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pumps such as Snq2, Yor1, Flr1, Atr1 [94-100] or defect in antioxidant activity [101]. 
To date, there is no evidence indicating that Imp2 directly regulates genes implicated 
in oxidative stress response [102]. It could manifest via a specific gene target that 
regulates by itself the expression of an efflux pump responsible for expelling 
bleomycin. 
 
1.4 Polyamines 
 
In spite of the fact that bleomycin is a hydrophilic molecule unable to diffuse 
passively across the cell membrane [6], its spermidine substituent, which is positively 
charged, might have a role in the cellular uptake. In fact, as bleomycin has an affinity 
to a specific transporter (Agp2) responsible for its uptake [87], probably through the 
recognition of the polyamine region, then it must have an affinity to efflux pumps, 
that are specific to polyamines such as spermine, spermidine and putreschine. These 
polyamines are natural and small molecules; they are water soluble and have an 
aliphatic carbon chain that is positively charged [103]. 
 
1.4.1 Polyamine synthesis pathway 
 
The polyamine synthesis pathway is initiated by the conversion of arginine – 
resulting from the urea cycle – into ornithine. The latter is decarboxylated to form 
putrescine through the action of the ornithine decarboxylase (ODC) enzyme. 
Meanwhile, S-adenosyl methionine (SAM), known to be involved in methyl group 
transfers, is converted to a decarboxylated form (DAM) by the adenosylmethionine 
decarboxylase enzyme (SAMD). The decarboxylated S-Adenosyl methionine donates 
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its aminopropyl group to putrescine to produce spermidine and spermine, by 
spermidine and spermine synthetase, respectively [104] . 
 
In the polyamine catabolism pathway, spermine and spermidine are acetylated to 
N-acetyl SPM and N-acetyl SPD, respectively, via SPM and SPD acethyltransferase 
enzyme (SSAT). These two acetylated polyamines could be converted back to 
putrescine through a catalyzation reaction mediated by flavin-dependent polyamine 
oxidase [104] . 
 
1.4.2 The importance of polyamine in the cell 
 
 Since polyamines are known to be positively charged, they bind to DNA, 
RNA and phospholipid macromolecules [105] that carry a negative charge, then get 
involved in many cellular processes including cell growth and proliferation, 
differentiation, chromatin structure, gene expression, transcription, signal  
transduction, membrane stability, ion transport, and cell signalling [106-108] . 
 
In recent studies, it has been reported that when polyamines bind to 
chromatin, they alter DNA and RNA synthesis by increasing or decreasing the 
accessibility of genomic sites for DNA and RNA synthetases. However, when 
polyamines are depleted, chromatin becomes more accessible to DNA digestion. 
Other studies supported that polyamines like spermidine and spermine play a role in 
DNA condensation and segregation, and induce DNA conformational transition 
[103]. 
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1.4.3  Polyamines related to cancer 
 
Polyamine levels are tightly regulated by their influx and efflux across the 
plasma membrane, in such a way that their level is never extremely low or high, 
which would result in either failure in supporting cell growth or toxicity [108-111]. 
 
Many studies focused on cancer research, have explored the polyamine 
biosynthetic pathway for the development of agents that inhibit tumor growth. It has 
been suggested that molecules such as methylglyoxal bis-guanylhydrazone (MGBG), 
known as a potent inhibitor of polyamine biosynthesis [112], inhibit the proliferation 
of 99% of many types of cancer cells in culture, and more than 95 % of transplanted 
cancers in animals. This occurs by the inhibition of the S-adenosyl methionine 
decarboxylase enzyme (SAMDC) that is involved in the polyamine pathway [103]. 
Thereby, the cell is depleted from its natural polyamines, and the toxic analogue of 
polyamine is then accumulated into the cell resulting in cell death. 
 
1.5  The transcriptional factor Yap1 
 
To search for possible efflux pumps,  a study was carried out that consisted of 
creating a multi-copy plasmid bearing the whole genomic DNA that derived from 
imp2 null mutant, and introduced into imp2Δ [102]. The main aim was to identify 
multi-copy suppressor genes that would restore the normal resistance to the imp2Δ 
mutant in response to bleomycin. This study showed that only 3 clones restored the 
normal phenotype, and all of them were carrying the entire YAP1 gene (Ramotar D., 
unpublished data), while no efflux pump gene was reported.  
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1.5.1 Yap1 structure 
 
Yap1 was isolated based on its ability to recognize and to bind to the 
recognition element TTAGTCA of virus 40 (Simian vacuolating virus) [113, 114]. 
Yap1 possesses 3 major domains: a basic leucine zipper DNA binding domain (bZip), 
a C-terminal cysteine-rich region (c-CRD) and an N-terminal cysteine-rich region (n-
CRD) [115] (Fig. 6). The bZip domain contains a leucine zipper domain necessary 
for dimerization of DNA, and a basic DNA binding domain, that share a homology 
with members of the mammalian Jun family of transcription factors, AP1. 
Because its bZip domain contains a DNA-binding domain, Yap1 was 
characterized as a member of the Jun family based on transcription factors [116]. 
 
NESNLS     bZIP
n-CRD c-CRD
60        150               279   313                           565            650
Yap1
 
 
Figure 6. Schematic structure of Yap1 
Yap1 comprises three conserved domains: a basic leucine zipper DNA binding 
domain (bZIP), a C-terminal cysteine-rich region (c-CRD) and an N-terminal 
cysteine-rich region (n-CRD).The Nuclear Localization Signal (NLS) is located at the 
N-terminal whereas the leucine-rich Nuclear Export Signal (NES) is located at C-
terminal. Adapted from Nature review [115]. 
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1.5.2  Role and mechanism of action of Yap1 
 
In Saccharomyces cerevisiae, the basic leucine-zipper transcription factor 
Yap1 [116] regulates the gene expression of antioxidant enzymes like the reactive 
oxygen species (ROS) – removing enzymes such as: SOD1-2  CTT1 and TSA1, and 
also the components of the cellular thiol-reducing pathways that include the REDOX 
group TRR1-2 GLR1 and GRX1, necessary for maintaining the cytosol in a reduced 
state by NADPH [117]. In addition, Yap1 plays a major role in response to H2O2 
[118, 119], and many electrophilic thiol-reactive chemicals such as N-ethylmaleimide 
(NEM), and the lipid peroxidation by-products 4-hydroxynonenal [120] and 
malondialdehyde [119]. 
 
Under non stress conditions, Yap1 is freely imported and exported from the 
nuclear compartiment [121, 122], whereas upon activation by oxidative stress – 
mainly caused by H2O2 [123], –Yap1 is rapidely redistributed in the nucleus because 
of the inhibition of its nuclear exportation [121, 124]. 
 
In response to oxidative stress, the Gpx3p Peroxidase (GPX)-like enzyme 
initially perceives the hydrogen peroxide signal, then transduces it to Yap1p resulting 
in the formation of two intramolecular disulfide bonds: one is between theYap1 N-
terminal CRD Cys
303
 and the C-terminal CRD Cys
598
 [117], and the other one is 
between the Cys
310
 and Cys
629
, it stabilize the activated form of Yap1 [125]. These 
two conformational changes mediate interactions with a conserved amino-terminal α-
helix [115], and therefore, mask the nuclear export signal sequence in the c-CRD (C-
terminal rich domain) of Yap1. This then becomes non-accessible to the Crm1 
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protein (β-karyopherin-like nuclear exporter), known to export Yap1 from the 
nucleus to the cytoplasm [121].  
As a result, the oxidized Yap1 accumulates in the nucleus, where it regulates 
the expression of up to 71 genes (one half is regulated by Yap1 alone, whereas the 
second half depends on both Yap1 and the transcription factor Skn7) [123, 126, 127], 
through its binding to the recognition element YRE: T (T/G) ACTAA [128-130] that 
is located within the promoter of target genes. 
 
1.6  Yap1 regulates the expression of efflux pumps 
 
It has been found that Yap1 does not regulate only antioxidants, but mediates 
drug resistance in Saccharomyces cerevisiae by regulating the expression of efflux 
pumps such as: Flr1p and Ycf1p [94, 131] which are involved in diazaborine 
resistance.  
 
1.6.1  Major Classes of efflux pumps 
 
Efflux pumps are subdivided into two main classes of pumps depending on 
their source of energy: ATP binding cassette (ABC) transporters and multifacilitator 
superfamily MFS. The ABC proteins are energized by ATP hydrolysis, while MFS 
proteins use the proton-motive force across the plasma membrane to translocate 
compounds [132-138]. 
 
Most of the efflux pumps specific to polyamines are part of the MFS 
superfamily. They are classified in 2 sub-families: DHA1 (the drug), H+ antiporter 
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families have 12 putative membrane-spanning helices; whereas the DHA2 family has 
14 predicted spanners [139]. Although it has been shown that many efflux pumps 
confer resistance to a range of structurally dissimilar compounds (including 
antibiotics and drugs) [140-142], the molecular mechanisms remain not well 
elucidated [141-146].  
 
1.6.2 Polyamines efflux pumps confer multi-drug resistance 
 
Among the 28 MFS [89] pumps identified to date in the Saccharomyces 
cerevisiae, 5 have been described: Tpo1, Tpo2, Tpo3, Tpo4 [147-150], Qdr3 [151, 
152], and also Qdr2 [150]. 
 
The QDR3 gene encodes an MFS efflux pump that belongs to the DHA1 
family [140]. It is located in the yeast plasma membrane [151, 152], and provides 
resistance to a variety of drugs including the polyamines [149], the antimalarial drug 
quinidine, the cisplatin, the bleomycin and the herbicide barban [152]. Its homologue 
– QDR2 – produces similar effects. A genome wide screen revealed that QDR3 also 
provides resistance to the antifungal drug fluconazole [153], selenomethionine [154], 
the antiarrhythmic drug amiodarone [155], and magnesium dichloride [156]. This 
screen was carried out by testing the sensitivity of the Qdr3 mutant to the drugs 
mentioned above. Unlike Qdr3, Qdr2 is involved in potassium uptake and might be 
capable of coupling K+ ion transport with the export of specific substrates such as 
quinidine, that have been shown to interfere with K+ uptake [157]. 
 
 20 
Besides Qdr2 and Qdr3, other efflux pumps have been described. Tpo1, Tpo2 
Tpo3 and Tpo4 are also members of the DHA1 family as drug: H+ antiporters.  
All of them share a similarity in their amino acid sequences [149], and thus 
have the same specificity to polyamine substrates like spermine, except Tpo1 and 
Tpo4 that are specific also to putrescine and spermidine, in addition to spermine 
[158]. Igarashi’group reported that TPO1, TPO2, TPO3 and TPO4 encoded specific 
polyamine transporters. They overexpressed each one of them, and then examined 
their role in response to methylglyoxal bis-guanylhydrazone (MGBG) [112], Co
2
+ – 
an inorganic bivalent cation – was used as a control since it does not have any effect 
on polyamine transport.The four overexpressed efflux pumps demonstrated resistance 
to 1 mM MGBG compared to the wild type, but not to Co2+, indicating that Tpo1, 
Tpo2, Tpo3 and Tpo4 transport specific polyamines [149]. 
This was confirmed by a northern blot experiment showing that cells 
overexpressing TPO genes have an increased level of their TPO mRNA expression, 
in response to 0.3 mM of spermine, but not as much as TPO1 mRNA, which was the 
most expressed compared to TPO2 TPO3 and TPO4 mRNA (Fig. 7). 
 
 
 21 
 
 
Figure 7. Northern blot analysis 
Each TPO gene was overexpressed and transformed into wild type strain. Wild types 
and transformed strains were cultured in the presence of 0.3mM of spermine. The 
expression level of TPO1, TPO2, TPO3 and TPO4 mRNA in wild types was 
compared to those overexpressing TPO genes by northern blot analysis Biochem 
Journal [149]. 
 
 
1.6.3 Characterisation of the MDR efflux pump Tpo1 
 
Although these proteins have been shown to confer resistance to a range of 
structurally dissimilar compounds (including antibiotics and drugs) [140-142], 
besides polyamines, Tpo1 [148], remains the best characterized efflux pump. It is 
involved in the extrusion of the artesunate [159], the herbicide 2, 4-D [160, 161], and 
the antimalarial drugs quinidine [162]. 
 
The TPO1 gene is located on chromosome XII and encodes a membrane 
protein consisting of 586-amino-acid residues [163], specific to putrescine, 
spermidine, and spermine.  
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In its structure, Tpo1 possesses (Fig. 8): 
- 3 glutamate acids Glu-207, Glu-324 and Glu-574, necessary for polyamine transport 
[149, 164]. 
- A long hydrophilic N-terminal region rich in serine and threonine residues, 
including serine 19, Threonine 52. These have been shown to enhance the activity of 
Tpo1 when phosphorylated by the protein kinase C [150]. 
- Ser 342, that is located in the cytoplasmic loop between the VI and VII 
transmembrane segment, helps releasing Tpo1 from the endoplasmic reticulum to the 
plasma membrane once it is phospohrylated by cAMP-dependent protein kinases 
[150].   
 
 
 
Figure 8. Model of Tpo1 structure 
The DHA1 efflux pump Tpo1 has in its N-terminal glutamic acid, serine and 
threonine residues, necessary for its transport activity. Adapted from Biochem 
Journal. [164]. 
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Tpo1 is mainly located on the yeast plasma membrane [147], and it catalyzes 
the efflux of polyamines at acidic pH, however when it is overexpressed, it is found 
in both plasma and vacuolar membrane. This has been demonstrated by a study 
showing that when Tpo1 is expressed from a single copy plasmid, it is detected only 
on the plasma membrane, whereas when it is overexpressed using a multi copy 
plasmid, Tpo1 is produced in many copies that will be located on plasma and vacuole 
membranes [150].  
 
1.6.4  The regulation of TPO1 by transcriptions factors 
 
The TPO1 gene includes within its promoter region many known specific 
binding sites that are recognized by specific transcription factors such as Pdr1, Pdr3, 
Skn7, Msn2, Msn4, Wrr1, and War1 (Fig. 9). These are involved in the 
transcriptional regulation of the gene depending on the type of stress that the cell 
undergoes [165].  
For example, in response to the stress induced by the antimalarial drug 
artesunate, TPO1 is dependent on the zinc finger Pdr1p for its transcriptional control 
[159]. It also requires Pdr3 – that shares 36% of its amino acid identity with Pdr1p – 
and Pdr1p, in case cells are under stress, caused by the chlorophenoxy herbicides 2-
methyl-4-chlorophenoxyacetic acid (MCPA) and 2,4-D [159, 160].  
 
Based on the YEASTRACT database (www.yeastract.com), the transcription 
factor Yap1 is found to activate the transcription of the TPO1 gene by binding to its 
recognition site YRE [159], when cells are exposed to oxidative stress (H2O2). 
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It has been shown by Sá-Correia’s group that Yap1 is involved in resistance to 
polyamine, since yap1 mutant exhibits an extreme sensitivity to spermine, 
spermidine and putrescine compared to the wild type [166]. Consistent with this 
finding, another study focused especially on the role of polyamine, and demonstrated 
that in presence of free iron, polyamines function as pro-oxidants able to induce 
oxidative stress [167]. This explains why Yap1 confers resistance to polyamine as it 
does to H2O2. 
 
Conferring resistance to polyamine does not necessarily mean that only one 
efflux pump is involved in polyamine detoxification. This might result from the 
transcriptional regulation of a set of genes specific to polyamine substrate such as 
TPO1 TPO2, TPO3, TPO4 and QDR3 [166].  
 
 
 
 
 
 
Figure 9. Position of consensus sequences recognized by transcription factors. 
Transcription fators control the regulation of TPO1 by binding to specific motifs. 
Yap1 recognized and binds to a concensus sequence located in 3 positions on the 
TPO1 gene: 994 (Forward strand), 29, 177 (Reverse strand). Adapted from 
Biotechnol.Review [159]. 
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1.6.5  The orthologue of TPO1 in human cells 
 
To date, no efflux pumps specific to bleomycin have been identified in 
mammalian cells. In the human genome, 48 ABC efflux pumps have been identified 
[168]. However, none of them have been shown yet to confer resistance to 
bleomycin, as Tpo1 does in saccharomyces cerevisiae.   
Based on blast search, a tetracycline transporter-like protein (TETRAN) has 
been the first MFS protein characterized in human cells as an orthologue to TPO1 
[169]. Since TETRAN shares some similarity with TPO1, it is that which is believed 
to expel specifically indomethacin (non-steroidal anti-inflammatory drugs (NSAIDs) 
in yeast. It is supported that TETRAN functions probably as an efllux pump in the 
same way as Tpo1 and  confers resistance to some NSAID when overexpressed 
[169]. Such a protein could lead us in further studies to check its specificity for other 
substrates and eventually bleomycin. 
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Since no efflux pump specific to bleomycin has been identified in mammalian 
cells, we decided to use the powerful genetic system of saccharomyces cerevisiae, the 
simplest and most well-known representative of eukaryotic cells, for evaluating toxic 
effects of bleomycin and characterizing potential efflux pumps that probably have 
their homologuous in mammalian cells and function similarly as in yeast. 
 
The main goal from this work is first to explore and understand how cells 
could develop resistance to the drug in yeast, then extrapolate the information from 
yeast to human. This will provide an insight into how cancer cells treated with 
bleomycin develop cancer. 
 
In this work, we provide evidence that Yap1 regulates the expression of the 
multidrug efflux pump TPO1 that in turn provides resistance to imp2mutants 
toward bleomycin. However, we still do not know if this regulation is direct, or 
mediated by other proteins such as the transcription factor Skn7p, since we know that 
half of the 71 proteins induced by oxidative stress depend on both Yap1p and Skn7p 
[127]. 
 
  
 
 
 
 
 
 
 
Chapter 2: Material and methods 
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2  Material and methods 
 
2.1  Yeast strains and growth media 
 
The yeast strains used in this work are listed in Table 1. Cells were grown 
either in YPD medium containing 1% Yeast Extract (MULTICELL) peptone (BIO 
BASIC INC) and 2% dextrose (BIO BASIC INC), or selective medias contained 
Yeast Nitrogen Base 10x (DIFCO), 2% dextrose (BIO BASIC INC), supplemented 
with the amino acids necessary for cells growth depending on the genotype. 
Solid media was obtained by the addition of 1.5% Agar (MULTICELL). 
 
 
Table 1. List of strains and their genotype 
 
Strains used in the present study: 
Strain Genotype Source 
 
By4741 (imp2Δ)  
By4741 (agp2Δ)  
By4741 (tpo1Δ)  
By4741 (tpo2Δ)  
By4741 (qdr3 Δ) 
By4741 (yap1
By4742 (parent) 
By4741 (parent) 
 
Isogenic to BY4741, except   imp2Δ::LEU2 
Isogenic to BY4741, except  agp2Δ::URA3 
Isogenic to BY4741, except tpo1::KAN 
Isogenic to BY4741, except  tpo2Δ::KAN 
Isogenic to BY4741, except  qdr3Δ::KAN 
Isogenic to BY4741, except yap1::HIS3 
MATα; his3Δ 1; leu2Δ 0; lys2Δ 0; ura3Δ 0 
MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0 
 
 
 
Lab 
strains 
collection 
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Strains made for the present study: 
Strains Genotype Source 
Wt (parent) / pYCP50 
Wt (parent) / pYAP1 
imp2Δ / pYCP50 
imp2Δ / pYAP1 
tpo1Δ / pYCP50 
tpo2Δ / pYCP50 
qdr3 Δ / pYCP50 
tpo1Δ / pYAP1 
tpo2Δ / pYAP1 
qdr3 Δ / pYAP1 
tpo1Δimp2Δ / pYCP50 
tpo2Δimp2Δ / pYCP50 
qdr3Δimp2Δ / pYCP50 
tpo1Δimp2Δ / pYAP1 
tpo2Δimp2Δ / pYAP1 
qdr3Δimp2Δ / pYAP1  
BY4741 / pYCP50 
BY4741 / pYAP1  
Isogenic to BY4741,except   imp2Δ::LEU2 / pYCP50 
Isogenic to BY4741,except   imp2Δ::LEU2 / pYAP1 
Isogenic to BY4741, except tpo1::KAN / pYCP50 
Isogenic to BY4741, except  tpo2Δ::KAN / pYCP50 
Isogenic to BY4741, except  qdr3Δ::KAN / pYCP50 
Isogenic to BY4741, except tpo1::KAN / pYAP1 
Isogenic to BY4741, except  tpo2Δ::KAN / pYAP1 
Isogenic to BY4741, except  qdr3Δ::KAN / pYAP1 
Isogenic to BY4741, except  tpo1 Δ ::KAN Imp2Δ::LEU2 / pYCP50 
Isogenic to BY4741, except  tpo2Δ::KAN  Imp2Δ::LEU2 / pYCP50 
Isogenic to BY4741, except  qdr3Δ::KAN  Imp2Δ::LEU2 / pYCP50 
Isogenic to BY4741, except  tpo1 Δ ::KAN Imp2Δ::LEU2 / pYAP1                  
Isogenic to BY4741, except  tpo2Δ::KAN  Imp2Δ::LEU2 / pYAP1 
Isogenic to BY4741, except  qdr3Δ::KAN  Imp2Δ::LEU2 / pYAP1  
 
 
 
 
 
 
 
 
 
 
This work 
 
Wt (parent) / pQDR3 
Wt (parent) / pTPO1  
Wt (parent) / pTW438 
imp2Δ/ pTW438 
imp2Δ/ pTPO1  
imp2Δ/ pMYC-TPO1 
imp2Δ/ pQDR3 
tpo1ΔImp2Δ / pTW438 
tpo1ΔImp2Δ / pTPO1 
tpo1ΔImp2Δ / pQDR3 
 
By4741 / pQDR3 
By4741 / pTPO1 
By4741 / pTW438 
Isogenic to BY4741, except   imp2Δ::LEU2 / pTW438 
Isogenic to BY4741, except   imp2Δ::LEU2 / pTPO1 
Isogenic to BY4741, except   imp2Δ::LEU2 / p MYC-TPO1 
Isogenic to BY4741, except   imp2Δ::LEU2 / pQDR3 
Isogenic to BY4742, except  tpo1 Δ ::KAN imp2Δ::LEU2 / pTW438 
Isogenic to BY4742, except  tpo1 Δ ::KAN imp2Δ::LEU2 / pTPO1 
Isogenic to BY4742, except  tpo1 Δ ::KAN imp2Δ::LEU2 / pQDR3 
 
 
 
 
 
 
 
This work 
 
Wt(parent)/ pYAP1-GFP 
imp2Δ/ pYAP1-GFP 
agp2Δ/ pYAP1-GFP 
 
BY4741 / pYAP1-GFP                                                  
Isogenic to BY4741, except   imp2Δ::LEU2 /pYAP1-GFP 
Isogenic to BY4741, except  agp2Δ::URA3 /pYAP1-GFP 
 
 
This work 
 
Wt: Wild type BY 4741 (parent)  
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Table 2. List of plasmids 
 
 
Plasmid Description and use Source 
 
pYCP50 
pYAP1 
 
pYAP1-GFP 
pTW438 
 
-URA3 plasmid used as an empty vector control. 
-URA3 plasmid containing YAP1 gene used for complementation of mutants 
lacking IMP2 gene. 
-URA3 plasmid with YAP1-GFP used for monitoring the localization of Yap1. 
-URA3 plasmid gap repair containing ADH promoter, MYC tag sequence. 
 
 
 
Lab 
plasmids 
collection 
 
 
  
pTPO1  
 
pQDR3 
pMYC-TPO1 
 
-TPO1 gene cloned into URA3 plasmid (pTW438) used for restoring  resistance 
to polyamines and bleomycin. 
-Same as above. 
-Same as above, but the restriction enzymes used are not the same. 
 
This 
work 
 
 
2.2  Spot test 
 
Yeast strains were inoculated in 1 ml of YPD liquid media and were grown 
overnight at 30 °C with agitation. The next day, cells were subcultured in 2 ml at 30 
°C on the rotary shaker. After 3-4 hours of subculture, cells reached exponential 
phase (OD: 0.6). Serial dilutions were performed, and from each one 4μl or 5 μl were 
spotted on agar plates contained or not different concentration of drugs: spermidine, 
spermine, bleomycin, 4NQO, and H2O2, depending on the experiment. Plates were 
incubated for two days at 30°C before being photographed by the ALPHA imager 
robot. 
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2.3  Spermidine excretion assay 
 
The strains By4741, imp2Δ were harvested at A600=0.5, then washed 2 times 
with a buffer containing 20mM Na/MES, pH 5.0 and 10 mM glucose, and 
resuspended in the same buffer. The excretion assay was initiated by the addition of 
3
H
 
spermidine (16.6 Ci /mmol Perkin Elmer) in 2ml of cells. Suspended cells were 
incubated at 30 °C with shaking for 0, 2, 4 and 6 min. After each incubation, cells 
were washed 3 times with the buffer described above supplemented with 1 mM of 
cold spermidine and resuspended in 400 µl of water. The radioactivity content was 
measured by adding 5 ml of scintillation liquid (Amersham Biosciences) to each 
sample, and using liquid scintillation spectrometry. 
 
2.4 Fluorescence microscopy 
 
We overexpressed the YAP1 gene as a GFP fusion gene into a wild type, 
imp2 and agp2 strains. Transformed cells were grown in 2 ml of selective liquid 
media –URA and harvested at OD600 0.5. Next, the cultures were diluted and 
incubated in the absence and presence of 0.5mM H2O2, and 18 mM spermidine for 10 
min and 30 min respectively. Cells were first fixed in methanol 50%, then stained 
with DAPI (4’,6-diamidino-2-phenylindoledihydrochloride) (DAPI; 2.5 pg/ml), and  
viewed using a Leica DMRE microscope. 
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2.5 Yeast transformation 
 
Depending on the genotype, strains were grown either in 1 ml of YPD liquid 
or 1 ml of selective media, over night at 30 °C. The following day, cells were sub-
cultured in a fresh media, for 3-4 hours. After incubation, they were washed twice 
with sterilized water followed by a quick spin (30 sec) at 1000 rpm. The pellet was 
washed with 600 ul of TE/LiAc solution (10 mM Tris - pH 7.5, 1mM EDTA, 100 
mM LiAc - pH 7.5), then centrifuged at room temperature and resuspended in 30 ul 
of the same solution which was sequentially supplemented with a list of components 
listed in the Table 2, below. 
 
Table 3. List of the components used for transformation 
 
 
             Samples 
Volume 
  Wild type or 
mutant strain 
                 Controls 
 
 
Cell culture 
 
SS carrier DNA 
 
Plasmid 
 
Empty vector 
 
PEG solution* 
 
30 µl 
 
5 µl 
 
 1-2 µl  
 
- 
 
           150 µl 
 
30 µl 
 
5 µl 
 
- 
 
1-2 µl  
 
150 µl 
 
30 µl 
 
5 µl 
 
- 
 
- 
 
    150 µl 
 
 
 
*PEG solution includes TE/LiAc 1 X and 50 % PEG (polyethylene glycol). 
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Cells were incubated at 30°C for one hour, followed by a heat shock in a 
water bath at 42
o
C for 15 min. Next, we microcentrifuged them at 3000 rpm for 1 
min, removed the supernatant and resuspended  their pellet in 100 µl of sterilized 
water by pipeting up and down. This volume was plated on YPD or appropriate 
selective agar plates that were then incubated at 30°C. The single colonies detected 
after 2-3 days, were patched on new agar plates. 
 
2.6  Bacterial transformation 
 
2.6.1  Chemical transformation using CaCl2 
2.6.1.1 Preparation of competent cells 
 
A single bacterial DH5colony inoculated in 2 ml of LB liquid, was grown 
over night at 37°C with moderate shaking. The following day, cells were subcultured 
in 50 ml LB for 4-5 hours at 37°C, followed by a spin down at 4°C for 10 min at 
4000 rpm. The supernatant was discarded while the pellet was washed twice with 
sterilized water, resuspended in 100 mM of cold CaCl2 and then chilled on ice for 1 
hour. After ice incubation, cells were spun down. The supernatant was then spun 
down and the pellet recovered. At this step, one can either place the tube containing 
suspension cells on ice for an immediate use or can add 100 mM CaCl2 and 50 % 
glycerol, then aliquote 50 µl of cells into 1.5 ml eppendorf tubes and store them at -80 
°C. 
Frozen competent cells will not be efficient beyond 4-6 months. 
 34 
2.6.1.2 Transformation of competent cells 
 
Competent cells already stored at -80 
o
C were thawed gently on ice. For each 
transformation, 25 µl was aliquoted into pre-chilled 1.5 ml eppendorf tubes, and then 
1-2 µl of DNA (plasmid of genomic DNA) was added to the aliquot. At this step, 50 
µl can also be used instead of 25 µl. 
The tube containing the mix of the DNA and cells was incubated on ice for 30 
min followed by a heat shock in a water bath at 42 °C for 90 sec.  
After that, the tube was left on ice to cool for 1-2 min, then 1 ml of LB was 
added to the culture and incubated in the shaker at 37 °C for 1-2 hours. 
After incubation, cells were spun down at high speed for 5 min and the pellet 
was recovered only with 200 µl of its supernatant. This was then plated onto LB agar 
media supplemented with 100 µg/ml Ampicillin. Plates were inverted and incubated 
at 37 °C over night. After 14-16 hours bacterial colonies appeared. 
 
2.6.2 The electroporation 
2.6.2.1 Preparation of electrocompetent cells 
 
A single bacterial DH5colony picked from the LB plate or from the frozen 
glycerol stock of bacterial cells, was inoculated into 3 ml LB media liquid, and 
incubated over night at 37°C in the shaker. The next day, cells were subcultured in 30 
ml of fresh LB media at 37°C. After 4-5 hours of incubation, cells were washed with 
MiliQ water 3 times and centrifuged at 4°C for 10 min at 4000 rpm. The pellet was 
re-suspended in 20 µl of miliQ water for immediate use. 
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2.6.2.2 Electroporation of electrocompetent cells 
 
0.5 -1 µl of transforming DNA was added to 20 µl of electrocompetent cells, 
the content was mixed gently, then placed  along walls of a 0.1 cm prechilled cuvet 
on ice for 30 min. After the incubation, cells were electroshocked according to the 
conditions below: 
-The voltage: 2.5 kV 
-The capacitance: 25 F  
-The resistance: 200 ohm 
-Time constant: 2.5-2.6 
Once cells are electroporated, 0.5 ml of LB media is added immediately, and 
the transformed cells are transferred to a 1.5 ml eppendorf tube then incubated at 37 
°C for 30-60 min. After the incubation, cells were spread on LB agar media + 
100ug/ml Ampicillin, and incubated at 37 °C over night. After 14-16 hours bacterial 
colonies appeared. 
 
2.7. Plasmid extraction from E.Coli 
 
One single colony picked from a LB/Amp transformation plate, was 
inoculated into 4 ml LB liquid containing 100ug/ml Ampicillin, and grown over night 
at 37°C in the shaking incubator. The next day; the sample was centrifuged at high 
speed (4000 rpm) for 10 min. The supernatant was carefully poured-off and the 
bacterial pellet was resuspended in 0.1 ml of solution 1 (50mM glucose, 25 mM Tris-
HCl - pH 8.0 and 10 M EDTA - pH 8.0). 
 36 
Next, 0.2 ml of solution 2 (1% SDS, 0.2 N NaOH) was added, and the 
contents was mixed by inverting the tube gently 5 times, then the tube was left to 
stand at room temperature. After 5 min of incubation, 0.15 ml of solution III (3 M 
potassium acetate K+, 5M glacial acetic acid) was added, and then the tube was 
incubated on ice for 10 min, and centrifuged at 12000 rpm for 5 min. 
In order to get rid of cell debris, the supernatant was transferred to a new 
eppendorf, to which was added 300 µl phenols twice, followed by adding the same 
volume of chloroform, twice also. The DNA was pelleted by centrifugation at 12000 
rpm for 5 min, washed with ethanol 95%, and then span down at the same speed for 3 
min.  
After this step, the ethanol was poured out and the pellet was dried in the fume 
hood. Once the ethanol had evaporated, we dissolved the pellet in 50 µl of dH2O, then 
stored it at -20 °C.If necessary, before storing, the DNA can be incubated with RNase 
for 30 min at 37 °C, however this step is not required in case  we use the plasmid 
mini-prep kit. 
 
2.8. Yeast Genomic DNA extraction 
 
2.8.1  The procedure for extracting genomic DNA 
 
Yeast cells were grown in 5 ml of appropriate media over night at 30°C. Next, 
they were centrifuged in 15 ml conical tubes at 4000 rpm for 1 min at 4 °C and then 
resuspended in 200 µl of breaking buffer (TE, 100 mM CaCL2 and 0.1 % SDS) by 
vortexing. We added sequentially 200 µl phenol: chloroform: IAA (12:24:1) followed 
 37 
by 200 µl of acid washed glass beads (425-600 micron). We capped the tubes tightly, 
and vortexed them for 2 min by placing them inside a mini bead beater. After 
repeating this step 2 times more, we spun the cells for 5 min at 15000 rpm to separate 
the lysed cells from the upper phase that we collected in a new tube. 
300 µl of 6M NaI and 10 µl glassmilk were added and mixed with 100 µl of 
supernatant. After 5 min of vortexing at high speed, the sample was pelleted by 
centrifugation and washed 3 times with 400 µl of new wash buffer. After the last 
wash, we let the tube drain at room temperature on a clean paper towel until the pellet 
get dried , then resuspended in 10-100 µl of dH2O. 
At this point, the sample could be centrifuged to separate the glassmilk from 
the supernatant containing dissolved DNA then used immediately, or alternatively 
stored at -20 °C. 
 
2.8.2  Purification of extracted genomic DNA 
 
In order to purify the extracted genomic DNA, 1/10 volume of 3 M NaAc and 
2 volumes of 100% ethanol were added and mixed with the sample by inverting the 
tube many times, before incubation at -80°C for 30 min. 
Next, the sample was spun down at 12000 rpm for 15 min, and the pellet was 
washed with ethanol (70%) followed by a short spin down (1 min). Finally, the pellet 
was air-dried and the DNA was resuspended in 20 µl of dH2O and stored at -20 °C. 
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2.9  RT-PCR 
 
2.9.1  RNA extraction 
 
RNA was extracted using a RiboPure-Yeast extraction kit (Ambion). 3 ml of 
yeast culture, grown overnight at 30 °C, was centrifuged at high speed. We discarded 
the supernatant while resuspending the pellet in 480 μl Lysis Buffer followed by 48 
μl 10% SDS and 480 μl Phenol: Chloroform: IAA. After adding these lysis reageants, 
we transferred the cell mixture to the tubes already filled with 750 µl of cold zircona 
beads. Tubes were capped tightly then vortexed at high speed by using the bead 
beater. After 10 min of vortexing, cells were spun down at 16,000xg for 6 min to 
separate the pellet and the beads from the aqueous phase containing RNA that we 
transferred to 15 conical tubes. 1.9 ml binding buffer, followed by 1.25 ml ethanol 
(100%) were added and mixed thoroughly with the partially purified RNA. This RNA 
mixture was drawn through the filter cartridge, collected in new tubes, then 
centrifuged for 1-2 min at high speed. Once done, we washed the filters with wash 
solutions (700 µl of wash solution 1, 500 µl of wash solution 2/3, twice). They were 
then transferred to new tubes in which we eluted the RNA in 25-50 µl of elution 
solution. 
 
Once the RNA is isolated, it is recommended to treat it with DNase since 
RNA contains chromosomal DNA. In order to remove contaminating DNA, we 
incubated 50-100 µl of the RNA sample with 4 μl DNase I (8 U) in 1/10 volume 10X 
DNase 1 buffer at 37 °C in a water bath. After 30 min of digestion, we inactivated the 
DNase by adding 0.1 volume DNase inactivation reagent, and then we let the reaction 
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stand at room temperature for 5 min. The sample was centrifuged for 2-3 min at 
10,000 xg. Finally the total RNA was transferred to a new tube and its absorbance 
was measured at 260 nm. 
 
2.9.2  RNA denaturing agarose gel electrophoresis 
 
10 ml 10X MOPS running buffer (0.3 M MOPS - pH 7.0, 0.1 M sodium 
acetate,0.01 M EDTA)  and 18 ml of 37% formaldehyde were added to 1 g agarose 
already dissolved in 72 ml water. The gel was poured, then covered by 1X MOPS 
running buffer. For RNA samples, we added 0.5-3X volumes of formaldehyde load 
dye to 1-3 µg RNA, before heating the sample to 65-70°C for 5 min to denaturate 
RNA, and then loading it. 
 
2.9.3  The synthesis of cDNA 
 
For cDNA synthesis, we added 0.2 µl of random primers and 1 µl of 10 mM 
dNTP to each RNase free tube containing 2 -5 µg of total RNA and we filled it to 12 
µl with sterilized distilled water. The mixture was heated to 65 °C for 5 min, and 
immediatly cooled on ice. We  spun down the sample then added 4 µl 5X First-Strand 
Buffer, 2 µl 0.1 M DTT and 1 µl RNase OUT
TM 
(40 units/µl). We mixed gently the 
sample that we placed in a water bath at 37 °C for 2 min. After 2 min of incubation, 1 
µl (200 units) of M-MLV RT (Reverse transcriptase) was gently mixed with the 
contents of the tube that we incubated for 10 min at 25 °C, 50 min at 37°C, and 15 
min at 70 °C. At this step cDNA is ready to use as a template for PCR reactions. 
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2.9.4  PCR reaction 
 
We designed the following primers using Gene Runner software, to assess the 
expression level of TPO1 and QDR3: 
-RT-PCR-TPO1-F:  5'- TTATATCGCACAAAGAACTACC-3'  
-RT-PCR-TPO1-R: 5'- GCATAATGATAGGCCTCGTC-3' 
-RT-PCR-QDR3-F: 5'- ATGCAAGCCCAAGGTTCAC-3' 
-RT-PCR-QDR3-R: 5'- TCCTCACTCTTCAACCTAC-3' 
 
We used the following primers already designed by a previous student, to 
detect the expression of AGP2, by using the ACTIN as a control: 
 
-RT-PCR-AGP2-F 5’-TTGATTGCTATTTCCGGTGTCA-3’ 
 
-RT-PCR-AGP2-R 5’GGGCCCTCCACGGTATAAAG-3’ 
 
-RT-PCR-ACT1-F1 5'- GTTTTGCCGGTGACGACGCTCCTCGTGCTG-3' 
 
-RT-PCR-ACT1-R1 5'-CGGCTTGGATGGAAACGTAGAAGGCTGGAACG-3' 
 
The master mix was prepared by adding these reagents: 1-4 µl cDNA, 5 µl 10 
X taq polymerase buffer, 1 µl of forward primer, 1 µl of reverse primer, 1 µl of taq 
polymerase (5U/µl) and 5 µl of 10mM dNTP. We filled up the tube with sterilised 
water to 50 µl. 
 
The PCR designed programs are: 
 
 
 -TPO1: 1- 95 ºC for 2 minutes, 2- 94 ºC for 0.5 minute, 3- 58 ºC for 0.5 minute, 4- 
72 ºC for 2.20 minutes, 5- 22 times repeat of steps 2-4, 6- 72 ºC for 7 minutes, and 7- 
4 ºC. 
 41 
-QDR3: 1- 95 ºC for 2 minutes, 2- 94 ºC for 0.5 minute, 3- 51 ºC for 0.5 minute, 4- 72 
ºC for 2.20 minutes, 22 times repeat of steps 2-4, 6- 72º C for 7 minutes, and 7- 4 ºC. 
 
-AGP2:1- 95 ºC for 2 minutes, 2- 94 ºC for 0.5 minute, 3- 55 ºC for 0.5 minute, 4- 72 
ºC for 2.30 minutes, 22-30  times repeat of steps 2-4, 6- 72 ºC for 2:30  minutes, and 
7- 4 ºC. 
 
2.10  Plasmid constructions  
 
2.10.1  Primers design 
 
We used the plasmid pTW438 as a substrate in the gap repair assay. It 
contains a Myc tag, URA cassette and an ADH promoter.  
It was digested with HindIII and SmaI. The linear DNA was gel purified. The TPO1 
and the QDR3 genes were amplified by PCR using genomic DNA of the strain 
BY4741 as a template, then purified. The following PCR primers designed for 
untagged TPO1 and QDR3 are:  
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Table 4. Design of PCR primers for TPO1 and QDR3 genes 
 
 
Primers for TPO1: The product size is 1.7 kbp 
Primers for QDR3: The product size is 2 kbp 
 
 
Table 5. Design of PCR primers for TPO1 gene tagged with MYC tag 
 
 
 
 
Name 
                    
Sequence 
 
TPO1-F 
 
 
TPO1-R 
 
5’-GCACAATATTTCAAGCTATACCAAGCATACAATAAGCTTCTCACC 
ATGTCGGATCATTCTCCCAT-3’  
 
5’-TATGTAACGTTATAGATATGAAGGATTTCATTCGTCTGTCGACCCT 
TAAGCGGCGTAAGCATACT-3’ 
QDR3-F 
 
QDR3-R 
5’-GCACAATATTTCAAGCTATACCAAGCATACAATAAGCTTCTCACC 
ATGCAAGCCCAAGGTTCACA-3’ 
 
5’-TATGTAACGTTATAGATATGAAGGATTTCATTCGTCTGTCGACCC 
TTAATCAATTTTGTCGTACA-3’ 
 
Gene Sequence 
 
MYC-TPO1-F 
 
MYC-TPO1-R 
 
5'-ACCATGGCGTCCGAGCAAAAGCTCATTTCTGAAGAGGACTTGCGG 
TCGGATCATTCTCCCATTTC-3’ 
5’-TATGTAACGTTATAGATATGAAGGATTTCATTCGTCTGTCGACCC 
TTAAGCGGCGTAAGCATACT-3’ 
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The same procedure was followed to amplify TPO1 as MYC tagged gene 
(Table 4), but instead of digesting pTW438 with HindIII and SmaI (Fig. 10 and 11); 
we used the restriction enzymes BamHI and SmaI (Fig 12).  
The PCR fragments were inserted into pTW438 between the 2 restriction sites 
mentioned above, near to the ADH1 promoter. 
 
 
 
 
 
Figure 10. Design of plasmid carrying QDR3 gene 
QDR3 gene was amplified and inserted into the digested plasmid pTW438, between 
the two restricted sites recognized specially by HindIII and Sma1. 
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Figure 11. Design of plasmid carrying TPO1 gene 
TPO1 gene was amplified and inserted into the digested plasmid pTW438, between 
the two restricted sites recognized specially by HindIII and Sma1. 
 
 
 
 
Figure 12. Design of plasmid carrying TPO1 gene tagged with MYC tag. 
TPO1 gene was amplified and inserted into the digested plasmid pTW438, between 
the two restricted sites recognized specially by BamH1 and Sma1. 
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2.11  Dissection of tetrads 
 
By4742 strain carrying pTPO1 was crossed with the double mutant 
tpo1imp2 that has an opposite mating type, by patching and mixing them onto the 
same YPD agar plate. The plate was incubated at 30 °C. After 24 hours, we picked 
grown colonies from the center of the cross, streaked them onto selective media plate, 
and placed them in the incubator at 30 °C. 1-2 days later, single colonies that resulted 
from the mating mixture had grown. They were inoculated in 3 ml of sporulation 
media (5 g KAc, 0.5 g yeast extract, 450 ml water), supplemented with the amino 
acids necessary for cell growth, and then incubated in the shaker at 30 °C for 3-5 
days. At the third-fourth day, cells were checked under the microscope to look for 
tetrads. Once diploid cells sporulated, we spun down 100-200 µl of cultures 
resuspended the pellet in 100 µl of 1M sorbitol and added 2 µl lyticase, required for 
the digestion of the ascus cell wall. 
 
After 15-20 min incubation at room temperature, sporulated cells were spread 
onto an inoculum area of predried selective media plate, then tetrads were dissected 
under the microscope using a Singer micro-manipulator robot. Once done, the 
dissection plate was placed at 30 °C then printed after 2-3 days of incubation to 
different selective media in order to determine the genotype of each grown colony. 
  
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 
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3  Results 
 
3.1 imp2 mutants are hypersensitive to bleomycin and polyamines 
 
It has been recently reported that strains lacking IMP2 gene exhibit parental 
resistance to UV light and methyl methane sulfonate. This resistance is not apparent 
for bleomycin, which induces strand breaks resulting in 15-fold increases in the 
sensitivity of imp2 mutants compared to the wild type [93]. The IMP2 gene does not 
possess any binding domain but it has a C-terminus leucine- rich repeat (LRR) 
domain, believed to mediate protein-protein interactions [170, 171], once IMP2 gets 
activated by phosphorylation under stress conditions. According to these finding, it 
has been suggested that Imp2 functions as a transcriptional factor that regulates the 
expression of genes required for preventing oxidative damage [93]. However the 
mechanism through which Imp2 confers resistance remains unclear. 
 
In this work, we decided to check whether the imp2 mutant, derived from 
By4741 background, presents sensitivity to bleomycin as it was seen in the case of 
imp2 isogenic to W303. Besides bleomycin, we used polyamines, since we 
know that they might act as pro-oxidants in the presence of free iron [104], and 
therefore induce oxidative stress as bleomycin does by generating free radicals. The 
main goal from using these two drugs is because both are related to cancer [13-15, 
104]. 
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Spot tests revealed that the imp2Δ mutant was extremely sensitive to 
bleomycin (1.5 µg/ml) as well as spermidine (15 mM), compared to the wild type. 
However, in response to 4-nitoquinoline-1-oxide (4NQO), a drug that normally 
causes bulky lesions onto the DNA, the mutant presented normal sensitivity, 
comparable to the wild type (Fig. 13). A similar result has been observed when the 
imp2Δ mutant was treated by DNA damaging agents such as the alkylating agents 
MMS, UV light and 4NQO [93], thus we exclude any role of Imp2 in DNA repair. 
Based on these results, the imp2 mutant appears to be hypersensitive only to 
oxidative DNA damage resulting in the accumulation of DNA breaks, suggesting that 
Imp2 is required especially for the detoxification of bleomycin and polyamines and 
not for DNA repair. 
 
Next, we checked whether the sensitivity displayed by imp2Δ toward drugs, is 
indeed due to the accumulation of polyamine and bleomycin. In this case we 
monitored the excretion of radiolabelled spermidine in the imp2 mutant during a 
time course from 0 to 6 min. As shown in figure 14, imp2Δ accumulated rapidly more 
labeled polyamines than the wild type and did not expel the excess as the parent 
strain does. This data is consistent with the previous result observed in figure 13, and 
indicates that the increased sensitivity to polyamine might occur at the efflux level. 
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Figure 13. imp2 null mutants displayed more sensitivity to bleomycin and 
spermidine compared to the wild type. 
Cells were grown to exponential phase, and then serially diluted as indicated. 5 µl 
from each culture was spotted onto YPD agar media with and without different 
concentrations of BLM, 4NQO and SPD. After 2 days of incubation at 30°C, plates 
were photographed using an alpha imager machine. This result is representative of 3 
independant spot tests. 
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Figure 14. The excretion assay of 
3
H spermidine during the time course 0-6 min. 
Exponentially growing cells were diluted to OD: 0.5 then incubated with 
3
H 
spermidine for 0, 2, 4 and 6 min. After each incubation, cells were washed three 
times, and then resuspended in a specific buffer, as described in materials and 
methods.The radioactive content was measured by liquid scintillation spectrometry. 
This result is representative of 2 independant assays. 
 
 
3.2 The multicopy plasmid bearing YAP1 gene restores bleomycin and 
polyamine resistance to imp2Δ mutant 
 
To confirm that Imp2 is required for polyamine and bleomycin detoxification, 
we decided to use it as a tool in order to look for their potential target genes. It was 
already shown that the IMP2 gene is not involved in the DNA repair mechanism, 
since the mutant displayed normal sensitivity to the DNA damaging agent 4NQO, in 
the same way as the wild type. It might therefore be expected that the IMP2 gene will 
regulate the expression of an efflux pump that can reduce the accumulation of the 
bleomycin and polyamines by increasing their efflux from the cell. Such a 
mechanism has been identified as the major one that provides resistance to cancer 
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stem cells in human [90].  
To search for possible efflux pumps, an experiment has been done by 
Dindial’s group that consists of cutting the whole genome of imp2 null mutant to 
fragments inserted into multi-copy plasmids [102]. The plasmids carrying these 
fragments were subsequently transformed into imp2Δ mutants, in order to check 
whether they will restore bleomycin resistance or not. As a result, three clones 
exhibited resistance to bleomycin, resulting from the overexpression of a gene that 
does not encode an efflux pump in the way one might expect. Instead, it encodes a 
transcriptional activator, Yap1p. 
 
Yap1p plays a major role in the regulation of most known cellular antioxidant 
genes [117], and it is involved in mediating multidrug resistance, by regulating the 
expression of efflux pumps such as the membrane pump Ycf 1p, the vacuolar pump 
Flr1p (that has been shown to confer resistance to diazaborine) [94, 131], and the 
Atr1 efflux pump [95] (that provides resistance to aminotriazole) [172]. 
 
To confirm whether Yap1p is responsible for restoring BLM resistance to 
imp2 mutant, we used the multicopy plasmid carrying the entire sequence of the 
YAP1 gene and then we introduced it into the mutant to check for any 
complementation. In parallel, we introduced an empty vector into the same strain as a 
control.As shown in figure 15, pYAP1 plasmid restored a partial bleomycin and 
spermidine resistance to the imp2Δ mutant compared to the wild type (+/- Ycp50), 
whereas in response to spermine, the rescue was more than partial at 0.2 mM , but not 
as significant at high doses.  
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As a control, we used 4NQO again, to make sure that the resistance observed 
in spot tests, is not due to the inability to repair DNA damages, but is due to the 
expression of efflux pumps. 
In response to 0.5µg/ml of 4NQO, we observed that the overexpression of 
Yap1 conferred resistance to strains carrying pYAP1, while the wild type (+/- Ycp50) 
was extremely sensitive (Fig. 15). This could be explained by the fact that Yap1p 
stimulates the expression of the ABC efflux pump Snq2 [173], that has been shown to 
be involved in the resistance to 4NQO [96, 174]. These findings provide evidence 
that Yap1 overexpression might activate an efflux pump in the imp2Δ mutant that 
expels both bleomycin and polyamines. 
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Figure 15. The complementation with pYAP1 restored resistance to imp2Δ. 
Cells were serially diluted after reaching the exponential phase, and then 4 μl from 
each culture, was spotted on YPD solid media with and without different 
concentrations of drugs as indicated above. After 48 hours of incubation at 30 °C, 
plates were photographed. This data represents 3 independent spot tests analysis. 
 
 
3.3 The single mutants tpo2 and qdr3 show parental resistance to 
polyamines and bleomycin, except tpo1 
 
In saccharomyces cerevisiae, 28 MFS efflux pumps have been identified [89]. 
Most of them have been shown to pump out a variety of toxic coumpounds [140-
142]. Such transporters are associated with multiple drug resistance (MDR), among 
them, Tpo1, Tpo2, [147-150] and qdr3 [151, 152] have been characterized. 
It has been reported recently that these pumps are required for polyamine 
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detoxification, and when they are deleted, cells exhibite sensitivity [166], and since 
bleomyicn includes in its N-terminal a chemical structrure similar to polyamine, we 
focused on the 3 pumps mentioned above, that might expel bleomycin besides 
polyamine. 
 
So based on these findings, we decided to mutate each one of these efflux, 
then check whether tpo1Δ, tpo2Δ, or qdr3Δ mutants would be sensitive to bleomycin 
as well as to polyamine. As shown in figure 16, none of the 3 single mutants showed 
sensitivity to spermidine even at high dose (30 mM). This result is in opposition to 
recent data [166] showing that in response to 10 mM of spermidine, tpo1Δ, tpo2Δ and 
qdr3Δ single mutants – that derived from the same background, By4741 – were 
extremely sensitive. In response to bleomycin, all mutants exhibited parental 
resistance, same as the wild type, except tpo1Δ that showed partial resistance. This 
suggests that Tpo1 might have a major role in bleomycin detoxification. 
However, this does not exclude the fact that Tpo1 alone cannot be enough to 
maintain optimal polyamine concentration in the cell, when cells are exposed to high 
and toxic doses. This means that the polyamine resistance observed in single mutants, 
results from the effect of multiple efflux pumps that compensate the lack of one 
efflux. 
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Figure 16. tpo1 exhibited partial resistance to bleomycin compared to tpo2 
and qdr3 
At OD: 0.6, cells were diluted and then spotted on YPD agar media with and without 
different doses of drug, as indicated above. Plates were photographed after 48 hours 
of incubation as was done in previous spot tests. These data are representative of 4 
independant experiments. 
 
 
3.4 The activation of TPO1 via the overexpression of Yap1, confers 
bleomycin and spermidine resistance to imp2Δ mutant 
 
Based on the Yeastract database, TPO1, TPO2 and QDR3 have been found to 
have specific domain located within their promoter region that is recognized 
especially by Yap1p. This suggests that these efflux pump genes might be 
upregulated by the transcriptional factor yap1 in response to oxidative stress. 
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To test whether TPO1, TPO2 and QDR3 genes are dependent on Yap1p, we 
constructed double-mutants tpo1Δimp2Δ, tpo2Δimp2Δ and qdr3Δimp2Δ, and then we 
checked whether pYAP1 would rescue them as it does in the previous spot test 
experiment, when it restored bleomycine and polyamine resistance to the imp2Δ 
mutant. The double mutants tpo2Δimp2Δ and qdr3Δimp2Δ displayed similar 
sensitivity to that observed in imp2Δ in response to 7.5 mM of spermidine, whereas 
tpo1Δ imp2Δ showed higher sensitivity (Fig. 17). This suggests that among these 
efflux pumps, Tpo1 plays a major role in the detoxification of bleomycin and 
polyamines. 
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Figure 17. tpo1Δimp2Δ exhibited higher sensitivity toward drugs compared to 
other double mutants. 
Cells were adjusted to OD: 0.6 then 5 µl was spotted onto YPD agar media, with and 
without different doses of SPD and BLM, as indicated above. Plates were incubated 
at 30 °C for 48 hours, and then photographed as was done in previous spot tests. Data 
are representative of 3 independent experiments. 
 
 
The introduction of pYAP1 into tpo2Δimp2Δ and qdr3Δimp2Δ mutants restored 
completely the resistance to spermidine, as compared to imp2Δ carrying pYAP1, but 
only partially restored resistance for tpo1Δimp2Δ (Fig. 18). 
We can reasoned that the deletion of TPO1 into tpo1Δ imp2Δ that resulted in a 
partial resistance to spermidine, was probably provided by other efflux pumps, maybe 
Tpo2 and Qdr3, or possibly others with/(out) a dependence on Yap1. 
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  The full resistance displayed by tpo2Δimp2Δ and qdr3Δimp2Δ double 
mutants, is mainly due to the role of Tpo1 in pumping out the drug.  
These data raise the possibility that Tpo1 is indeed a potential candidate 
required for bleomycin and spermidine efflux, probably in the dependency of the 
transcriptional factor Yap1 since this has been shown to be the major determinant of 
polyamine (spermidine) stress resistance [166]. 
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Figure 18. pYAP1 rescues partially tpo1Δimp2Δ but completely tpo2Δimp2Δ and 
qdr3Δ imp2Δ 
 
As described in previous spot tests, diluted cells were spotted onto YPD agar media, 
with and without SPD and BLM. Plates were incubated at 30°C for 48 hours, and 
then photographed. These data are representative of 3 independent analyses. 
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3.5 The overexpression of Tpo1 confers resistance to imp2Δ mutant 
toward bleomycin and polyamine  
 
If it is true that Yap1 restored both bleomycin and polyamine resistance to the 
imp2Δ mutant through the activation of TPO1, then one might speculate that the 
overexpression of Tpo1 would substitute for Yap1. 
The TPO1 gene was cloned into multi-copy plasmid pTW438 bearing the 
strongest promoter ADH, leading to Tpo1 overexpression. The plasmid carrying 
TPO1 was then introduced into the single mutant imp2Δ, to check whether it would 
restore resistance as pYAP1 did in the previous results. As a control, we introduced 
an empty vector pTW438 into the same mutant. In parallel, we engineered the same 
construct to overexpress QDR3 as a control, since it has been found to be under the 
regulation of a second transcriptional factor, Yap1, besides Gcn4 when, cells are 
exposed to polyamines [166]. 
 
The overexpression of Tpo1 provides more resistance to imp2Δ in response to 
bleomycin and polyamines as compared to the imp2Δ mutant carrying pQDR3, and 
the control carrying the empty vector does not show any resistance to the drug, as it 
would be expected (Fig. 19). On the basis of these findings, it seems that Tpo1 efflux 
is more critical than Qdr3 to the detoxification process. 
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Figure 19. pTPO1 restores resistance to imp2 mutant towards drugs. 
0.4 µl of diluted cells was spotted onto YPD agar media, with and without the 
indicated concentrations of SPD, BLM and SPM. Plates were incubated at 30 °C for 
48 hours, and then photographed. These data are representative of 3 independent 
analyses. 
 
 
We expected that in response to bleomycin, pTPO1 would confer to imp2Δ 
similar resistance to that provided by pYAP1 as shown in figure 15, but this was not 
the case. A first possible explanation is that the partial resistance displayed by 
imp2/pTPO1 and imp2 was due to the effect of BLM-A5, which is more toxic 
than the 2 major components A2 and B2 of the blenoxane [175].  
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A second explanation could be that the endogenous polyamines might 
compete with the bleomycin by reducing its efflux, resulting then in the accumulation 
of the drug in the cell rather than its efflux and degradation. Although pTPO1 did not 
confer the same level of resistance, this does not exclude that TPO1 could be 
dependent on Yap1 in response to bleomycin and polyamines. 
 
Next, we tried to overexpress Tpo1 into the double mutant tpo1Δ imp2Δ, by 
using the LiAC transformation method to introduce the gene as we did before. 
Surprisingly no clones were grown in the media. Since we know that Imp2p is 
involved in maintaining cation homeostasis, including Na+ and Li+ [102], the failure 
of cell transformations could be due to the sensitivity of strains to lithium resulting in 
their growth inhibition. So we exposed the wild type, imp2Δ, tpo1Δimp2Δ and   
qdr3Δ imp2Δ strains to different concentrations of lithium starting from 100 mM 
which is the same dose used in the transformation method (material and methods). 
 
As shown in the figure 20, strains lacking IMP2 gene displayed resistance to 
100 mM of lithium compared to the wild type, and even at high concentrations, the 
resistance was maintained through the expression of genes that act independently of 
Imp2p, such as HAL3 and ENA1. This is supported by the fact that the pHal3 protein 
promotes Li+ resistance to imp2Δ by stimulating the expression of the ATPase efflux 
Ena1p [102]. Based on these data, it appears that lithium was not the main cause of 
cell growth inhibition, even after modifying the yeast transformation parameters, the 
result remained the same. Subsequently, we decided to use instead the dissection of 
tetrad as an alternative method, and check the expression of the pTPO1 by RT PCR 
(Fig. 21). 
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Figure 20. Lithium does not affect the phenotype of the wild type and mutants. 
0.4 µl of serially diluted cells was spotted onto YPD agar media, with and without 
different concentrations of lithium. Plates were incubated at 30 °C for 48 hours, and 
then photographed.  
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Figure 21. Expression of pTPO1 and the endogenous TPO1 gene. 
RT PCR analysis indicates the expression level of the endogenous TPO1 compared to 
that overexpressed 
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The Introduction of the pTPO1 plasmid into the double mutant restored 
parental resistance to both bleomycin and polyamines compared to the wild type. In 
contrast, although Qdr3 is believed to be involved in SPD efflux, its overexpression 
did not provide resistance to tpo1Δ imp2Δ (Fig. 22), meaning that Qdr3 is not a 
potential efflux pump like Tpo1. 
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Figure 22. Overexpression of TPO1 restored full resistance to tpo1Δimp2Δ 
towards BLM and SPD. 
Cells were spotted onto YPD agar media, with and without the indicated 
concentrations of BLM and SPM. Plates were incubated at 30 °C for 48 hours, and 
then photographed. These data are representative of 3 independent analyses. 
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Based on the result 19, it is likely that the resistance conferred to 
imp2Δ/pQDR3 is mainly due to the expression of Tpo1, which is consistent with the 
result 22 showing that the overexpression of Qdr3 does not rescue tpo1Δimp2Δ.  
In addition, we believe that unlike pYAP1, the overexpression of Tpo1 
conferred parental resistance to imp2Δ tpo1Δ because in this case, Tpo1 could be 
located in both plasma and vacuolar membranes as it has been demonstrated 
previously [150]. This means that the drug would not only be pumped out from the 
cell, but it would be also degraded into the vacuole once it is transported across the 
vacuolar membrane by Tpo1, resulting in higher resistance towards bleomycin and 
polyamines. 
 
We postulated that Tpo1 behaves as a polyamine efflux that is dependent on 
Yap1 in stressful conditions; however there is no evidence indicating that it is the 
only transcription factor required. We found that cells lacking the YAP1 gene 
exhibited parental resistance to spermine as well as bleomycin (Fig. 23). This is 
contradictory to recent data showing that the same cells were not resistant in the way 
we have shown, but instead they were extremely sensitive to higher concentrations of 
polyamines (4mM spermine and 10 mM spermidine) [166]. If Yap1 was the only 
factor required fot TPO1, yap1 mutants would be sensitive not only to high doses, 
but also to low doses of polyamines, and since no data have shown this, we suggest 
that other transcriptions factors could be involved in the oxidative stress besides 
Yap1. 
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Figure 23. Cells lacking the YAP1 gene displayed parental resistance towards 
BLM and SPM. 
 Exponentially growing cells were serially diluted, then 0.4 µl of cells were spotted 
onto YPD agar media, containing different concentrations of BLM, SPM and, as a 
drug control, H2O2. Plates were incubated at 30 °C for 48 hours, and then 
photographed. 
 
 
3.6  Yap1-GFP does not localize to the nucleus of agp2Δ in response to 
spermidine   
 
In a separate experiment, Yap1 was overexpressed as a GFP fusion protein 
into the wild type, imp2Δ and agp2Δ in order to monitor its cellular localization in 
response to spermidine. Since it has been reported that Yap1-GFP accumulates in the 
nucleus of yeast cells after 30 min of spermidine exposure [166], we decided to check 
its localization in response to the same conditions and as a control, we treated cells 
with 0.5 mM of H2O2 for 10 min [176]. 
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As shown in figures 24B-C, under spermidine stress, Yap1-GFP is mainly 
located in the nucleus of imp2Δ and wild type strains. The same results were 
observed in response to H2O2. In contrast, we noticed that no Yap1-GFP protein was 
detected in agp2 Δ in response to spermidine, and in response to H2O2 few Yap1-GFP 
were detected (Fig. 24-A). 
Because of the deletion of AGP2 resulting in a decrease of spermdine uptake, 
Yap1-GFP cannot be located in the nucleus in response to spermidine treatment, as 
long as the polyamine content is maintained. Instead, Yap1 would accumulate in the 
cytoplasm. These finding arise the possibility that Agp2 might be related to Yap1. 
 
 
A ) agp2strain
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GFP-YAP1          DNA              Merge
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Figure 24. Cellular localization of Yap1-GFP in reponse to H2O2 and spermidine 
in the wild type, imp2Δ and agp2 Δ. 
Cells transformed with a plasmid bearing YAP1-GFP were treated (or not) with 0.5 
mM H2O2 for 10 min and 18 mM of spermidine for 30 min. Transformed cells are 
presented in this order: A) agp2 Δ mutant; B) Wild type; C) imp2Δ mutant. 
Yap1-GFP               DNA                  Merge 
Yap1-GFP            DNA                 erge 
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In addition, we performed an RT PCR (Fig. 25) to check the level of 
expression of Agp2 in strains overexpressing YAP1. 
Interestingly, strains harboring pYAP1 showed an important expression level 
of Agp2 under normal condition as compared to the wild type. A possible explanation 
is that as Agp2 imports endogenous polyamine molecules, the cell becomes 
concentrated in polyamine. This excess would therefore stimulate Yap1 to activate 
the polyamine efflux, in order to regulate the polyamine homeostasis. Although Yap1 
is not a transcription factor required for AGP2, the relation between Agp2 and Yap1 
needs to be further explored. 
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Figure 25. Expression of endogenous AGP2 gene. 
RT PCR analysis indicates the expression level of the endogenous AGP2 in cells 
overexpressing YAP1 compared to the wild type and imp2Δ. 
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4  Discussion 
 
In this study, we used the powerful genetic system of saccharomyces 
cerevisiae as a tool to search for determinants of resistance to bleomycin and to 
characterize the molecular transport machinery of Tpo1. 
TPO1 encodes a yeast plasma membrane multi-drug efflux pump that belongs 
to the major multi-facilitator superfamily (MFS) [89]. As shown in the result section, 
Tpo1 is mainly required to strengthen the polyamines as well as bleomycin.  
 
Herein, the purpose of using this efflux pump is that because we know that 
bleomycin includes a spermidine substituent that has an affinity to polyamine efflux 
pumps including the well characterized pump Tpo1. However, it should be noted that 
this finding is not a reason to exclude the other efflux pumps such as Qdr3 and Tpo2. 
Thus, we proceeded by mutating each one of these pumps and then assessed whether 
tpo1Δ, tpo2Δ, or qdr3Δ mutants would be sensitive to bleomycin or not. Interestingly, 
all the mutants exhibited parental resistance similar to the wild type towards 
bleomycin and spermidine except tpo1Δ, which was sensitive only to bleomycin. 
These results suggest that Tpo1 might be a specific efflux pump that is required for 
expelling bleomycin out of the cell, even if it is enough to maintain alone the optimal 
polyamine concentration without the contribution of other pumps. 
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To verify this, we first looked for a gene that when deleted, induces sensitivity 
to bleomycin in qdr3, tpo1 and tpo2 mutants. In this way, we would be able to 
check whether the bleomycin resistance would be restored by overexpressing the 
gene TPO1. Recent findings showed that the deletion of S. cerevisiae IMP2 gene, 
which encodes a transcriptional co-activator, (required for mediating cellular 
resistance to oxidative DNA damaging agents) induces hypersensitivity to bleomycin 
by 15-fold [93]. 
 
Based on this finding, we used IMP2 as a tool to make double mutants. Our 
data revealed that when TPO1, TPO2 and QDR3 are mutated in combination with 
IMP2, cells become extremely sensitive to bleomycin and polyamines, as well as the 
imp2 mutant alone. This led us to propose that Imp2 might regulate the expression 
of an efflux pump whether or not it is the only Tpo1. In contrast with this hypothesis, 
other reports suggest that the hypersensitivity exhibited by the imp2 mutant towards 
bleomycin, does not result from the deficiency of efflux pumps expression [94-100, 
131] as we thought. Nor is it a consequence of a defect in antioxidant activity [101], 
and it is not due to unrepaired DNA strand breaks [40], since imp2 mutants are 
known to be insensitive to ionizing radiations and MMS [92, 93].  
      
As we know, Imp2 controls several genes under stress conditions, so a 
plausible mechanism is that Imp2 might control the expression of target genes that in 
turn, regulate the expression of these efflux pumps. This might explain why the imp2 
null mutant uptakes more labelled spermidine during the time course (0-2-4 min) in 
the excretion spermidine assay, while the wild type uptakes less during the first 4 min 
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and then starts expelling the H
3
-spermidine in the next 2 min. This is probably due to 
the lack of a gene expression that normally requires Imp2 as a regulator. 
 
Over the years, many genes were identified by their ability to bind and 
activate efflux pumps, by enhancing cell resistance to stress conditions, among them; 
Yap1 remains the most known activating factor. Yap1 is a transcriptional factor 
involved in oxidative stress [118, 119, 123]. It regulates the expression of up to 71 
genes [126, 127] including efflux pumps genes –such as FLR1, YCF1, SNQ2 and 
PDR5- [94, 131, 177] upon exposure to stress. Further analysis demonstrated that 
Yap1 found in multicopy transformants, confers resistance to the iron chelators 1,10-
phenantroline and 1-nitroso-2-naphtol, to cycloheximide [178], as well as the 
anticancer drug bleomycin. 
 
According to these findings, we suspected that Yap1 could be probably the 
major regulator of TPO1, TPO2 and QDR3 genes, and if it is the case, it would 
restore bleomycin resistance to double mutants. Indeed, Yap1 restored BLM and 
spermidine resistance to tpo2Δimp2Δ and qdr3Δimp2Δ double mutant, except for 
tpo1Δimp2Δ that showed partial resistance to the drug. 
Based on the Yeastract database, the TPO1 gene includes in its promoter 
region three potential Yap1p response elements (YREs) [159] to which Yap1 binds, 
in order to activate the gene expression. Althoug QDR3 and TPO2 also include YRE 
within their promoter region, we reasoned that Tpo1 could be a major efflux pump 
required for Yap1 to restore drug resistance, since we believe that the resistance 
observed in both tpo2Δimp2Δ and qdr3Δimp2Δ resulted from the activation of TPO1 
via Yap1. 
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 If we assume that Yap1 restores bleomycin and polyamine resistance to the 
double mutants through the activation of TPO1 gene, then we expect that the 
overexpression of Tpo1 would substitute for Yap1. With this in mind, we designed a 
multi-copy plasmid pTPO1 in such a way to express TPO1 as a gene tagged with 
MYC tag in its N terminal. Spot test analysis revealed that the expression of the Myc-
Tpo1 fusion protein in the imp2 mutant did not confer resistance to bleomycin and 
polyamines (data not shown) as we were expecting. This could be explained by the 
targeting of Tpo1 to the vacuolar membrane when it is overexpressed and thus, 
stimulates the uptake of polyamines and BLM into the vacuole for detoxification.  
 
It has been reported that N-terminal of Tpo1 includes 2 major amino acids – 
serine 
19
 and threonine
52
 – that are essential for the regulation of Tpo1. The 
phosphorylation of Ser 
19
 and Thr
 52
 is necessary for enhancing the activity of Tpo1 
[150]. So, as it was tagged with Myc protein in its N-terminal, Ser 
19
, Thr 
52
 would 
not be phosphorylated. Therefore, as far as the drug is transported into the cell, it will 
accumulate causing toxicity, and that explains why imp2mutant overexpressing the 
tagged Tpo1 was extremely sensitive. Additionally, we decided to use an untagged 
TPO1 as long as it does not interfere with the function. When pTPO1 is 
overexpressed, it restored bleomycin and polyamine resistance to the imp2 mutant 
while in tpo1Δimp2Δ, it conferred parental resistance.  
Because Tpo1 is located in both plasma and vacuolar membrane once it is 
overexpressed [150], it expels the bleomycin out of the cell, then the drug is 
transported across the vacuolar membrane via Tpo1 and gets degraded into the 
vacuole. This explains why at high doses of bleomycin, pTPO1 was still rescuing the 
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double mutant. Similar results would be observed in the single mutant if we used 
BLM instead of BLM-A5. 
 
It is noteworthy that unlike pTPO1, Yap1 overexpression conferred resistance 
but not as much as the overexpressed Tpo1 does. Recent reports showed that when 
TPO1 is overexpressed in a single copy plasmid, it is found mainly on the plasma 
membrane [150]. This correspond to the normal  level of Tpo1 expression in the cell 
once it get activated, however, by using a multi-copy plasmid, Tpo1 is located on the 
plasma membrane and also the vacuolar membrane, so the more drugs entering the 
cell, the more are expelled. In turn there is transportation into the vacuole and 
degradation. This explains why double mutants were extremely resistant to the drug 
when Tpo1 was overexpressed. 
 
Since the resistance was restored in double mutants by overexpressing either 
Tpo1 or Yap1, we can conclude that Tpo1 is required for the detoxification process in 
dependency of Yap1p. This was supported by a recent study showing that the deletion 
of YAP1 gene induced a hypersensitivity to high doses of polyamines [166], in other 
word, the efflux pump Tpo1 would not be activated in cells lacking the transcriptional 
factor Yap1. This result was contradictory with our previous data, showing that 
yap1mutantsbecome resistant in response to polyamine and bleomycin rather than 
sensitive, suggesting that other transcription factors might be required to confer 
resistance to polyamine and bleomycin besides Yap1. 
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In the cell, under stressed conditions, we believe that Yap1 plays its role by 
providing resistance to oxidative stress, in the dependency of Agp2 protein. This 
hypothesis is consistent with the microscopy assay result showing that in response to 
spermidine, none of Yap1-GFP proteins were detected in the nucleus of 
agp2compared to the wild type, meaning that as long as the polyamine is not 
imported into the cell because of the lack of AGP2 gene, Yap1 cannot not be induced, 
and therefore it would not be redistributed in the nucleus.  
In another word, when cells are treated with bleomycin and polyamines, Agp2 
transports the drug across the yeast plasma membrane and gets inside. Each one 
molecule of bleomycin caused damage in a single DNA molecule [179, 180] and 
generated free radicals, resulting in oxidative stress. Under these conditions, Yap1 is 
transported from the cytoplasm to the nucleus, binds to the specific motif TGACTAA 
on the promoter of TPO1 and subsequently activates the expression of the gene 
encoding the efflux pump Tpo1 that in turn expels efficiently the drug. 
 
It cleary appears that Agp2 and Yap1 work dependently to maintain 
polyamine homeostasis when cells are challenged to oxidative stress. Surprisingly, 
the same observation was noted in the case of non-stressful conditions as shown in 
the RT PCR result. As we overproduced Yap1 in the wild type (not shown) and the 
single mutant imp2 (Fig.25), the expression level of Agp2 became enhanced. A 
possible explanation could be that Agp2 requires Yap1, even if it is not its 
transcription factor (YEASTRACT database). Therefore under normal conditions, the 
endogenous polyamine levels are tightly regulated by their influx and efflux across 
the plasma membrane, so when their level is low, Agp2 transports polyamines into 
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the cell in order to keep the intracellular concentration of polyamines optimal, 
however, as long as Agp2 keeps importing these compounds to the cell, their level 
become high even toxic, in this case, cells would be subjected to an oxidative stress, 
that in turn induces the Yap1 activity. Once Yap1 is stimulated, it will activate the 
expression of specific efflux pumps able to expel the excess of polyamines out of the 
cell. 
 
According to our recent data mentioned above and our interpretations, Yap1 
might be involved in the regulation of Agp2 in such a way that when Agp2 transports 
more bleomycin or polyamines to the cell, Yap1 gets involved to negatively control 
the AGP2 in order to prevent toxicity. Such a possibility needs to be further 
investigated. 
 
 
 
 
 
 
 
 
 
 
 78 
5 Conclusion 
 
In this work, we demonstrated that unlike Tpo2 and Qdr3, Tpo1 is a major 
MFS-MDR protein required for the polyamine and bleomycin detoxification process, 
with dependency on Yap1, and perhaps other transcription factors also. 
When cells are exposed to bleomycin or to high doses of polyamines, Yap1 
binds to its specific region onto the TPO1 gene, and then activates its transcription, 
resulting in the overexpression of the efflux proteins, that in turn, pump out either the 
toxic bleomycin or the excess of the exogenous polyamines (Schema 27) in order to 
maintain an optimal concentration of polyamine inside the cell. 
 
The identification of Tpo1 as a potential candidate has emerged from our 
results showing that when Tpo1 is overexpressed, it confers resistance to imp2as 
well as to the double mutant. However this does not exclude the fact that other efflux 
pumps might contribute to the efflux process in order to maintain cell homeostasis. 
Even if Qdr3 did not provide any resistance, its role could be minor compared to 
other efflux pumps. In addition, no evidence indicates that Tpo1 functions as a 
polyamine transporter only under the regulatory control of the transcription factor 
Yap1. Although we have shown that the overexpression of Yap1 provides resistance 
to imp2 and double mutants, by acting on the TPO1 gene, Yap1 seems not to be the 
only factor involved. 
 
 When we deleted the gene YAP1 in a separate experiment, we found that cells 
become resistant rather than sensitive, suggesting that other transcription factors are 
required to confer resistance besides Yap1. 
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Under normal conditions, Yap1 is found in the cytoplasm, whereas in 
response to oxidative stress caused either by H2O2 or a high dose of spermidine, it 
localizes in the nucleus of the wild type and imp2mutant strains, but not in the 
agp2 mutant. Since Agp2 is known to behave as a polyamine and bleomycin 
transporter, it seems logical to expect that when deleted, no exogenous polyamines 
enter to the cell, thus the intracellular concentration of polyamine remains optimal 
and none influenced. Such conditions, similar to unstressed conditions, do not 
stimulate Yap1 expression.  
 
All of this has helped to a better understanding of the functioning of Yap1 and 
Tpo1 in response to bleomycin. Although no TPO1 homologue has been identified in 
human cells as a bleomycin efflux, other efflux pumps could behave similarly to 
Tpo1. Once they are activated and overexpressed, they would decrease the 
intracellular concentration of chemotherapeutic agents by limiting their cytotoxic 
effect on healthy cells as well as cancer cells, these latters would continue growing 
instead of dying, and consequently invade other healthy tissue, and this explains why 
cancer cells are resistant to anti-cancer agents. 
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Figure 26. Predicted Model showing how the resistance to bleomycin can occur 
 
1) When cells are subjected to bleomycin treatment, Agp2 (polyamine and bleomycin 
transporter) transports the drug (metallobleomycin BLM-Fe
2+
) in the cell. In the 
presence of oxygen, the mettalobleomycin is converted to an activated form (BLM-
Fe
3+-
OOH). 2) The drug is then sequestreted into the vacuole as a mechanism of 
detoxification [181, 182]. 3) Once accumulated, some bleomycin molecules leak to 
the cytoplasm [183], and then reach the nucleus where their DNA target is located. 
Each molecule of bleomycin caused damage in a single DNA molecule [179, 180] 
and generated free radicals resulting in oxidative stress. 4) Under this stress condtion, 
Yap1 is transported from the cytoplasm to the nucleus, and then activates the 
expression of TPO1 gene, by binding to its YPE site located on the promoter of TPO1 
gene. 5) The activation of TPO1 transcription leads to the overexpression of Tpo1 
efflux pumps, which will pump the drug out of the cell. 
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